Paul Hastings LLP advised Xencor, Inc. (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, in connection with its $175 million underwritten public offering of common stock. The offering closed on September 12, 2024.

Chair of the Corporate practice in Palo Alto Jeff Hartlin and partner Deyan Spiridonov led the Paul Hastings team, which included partner Samantha Eldredge and associates Jenna Barba, Nina John, and Kevin DeCeoursty.

More details on the transaction can be found here.

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.